Company Profile
Phathom Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- PHAT
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Phathom Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
10.86 USD (+1.59%)
Close
Last updated: June 23, 2026 at 00:00
866.15M USD
Market cap
Why the stock is moving
PHAT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Phathom Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Phathom Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Phathom Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Source: Phathom Pharmaceuticals
- 03
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Source: Phathom Pharmaceuticals
- 04
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Source: Phathom Pharmaceuticals
- 05
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Source: Phathom Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals (PHAT) most recently closed at 10.86 USD, a +1.59% move versus the previous session.
What is the market cap of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals currently has a market capitalization of 866.15M USD on BioPharmSignal.
What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is PHAT stock listed?
Phathom Pharmaceuticals (PHAT) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Phathom Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Phathom?
Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Phathom Pharmaceuticals targeting with Phathom?
Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Pharmaceuticals?
Phathom Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.